title: Enzyme replacement therapy with agalsidase alfa in children with Fabry disease.
abstract: OBJECTIVE
  To assess the effects of enzyme replacement therapy (ERT) in children with Fabry disease.
  
  
  METHODS
  Safety and efficacy of ERT with agalsidase alfa, 0.2 mg/kg infused over 40 minutes every 2 weeks for 23 weeks, were studied in a multicentre open-label trial in nine boys and four girls. Median age at the start of the study was 11.0 years (range 3.5-18 years).
  
  
  RESULTS
  Fifty-four adverse events were reported in 11 patients. No serious adverse events related to ERT were reported. Twelve of the 54 adverse events were considered possibly or probably related to ERT. Infusion reactions (8 mild, 3 moderate) occurred in four boys, in seven infusions. One boy developed IgG antibodies, although he continued to make good clinical progress. At the end of the study, two of the four boys and the one girl on regular pain medication at baseline had stopped taking analgesics. Brief Pain Inventory (BPI) scores decreased in most patients by week 12 and were sustained until the end of the study. This change was greater in the boys, who had higher (worse) BPI scores at baseline. Pain-related quality of life (QoL) scores also decreased during the study. Plasma globotriaosylceramide concentrations and urinary globotriaosylceramide:sphingomyelin ratios decreased after 12 and 23 weeks of therapy, particularly in the boys. Increases in sweat volume were recorded in three out of five of the boys and in one of two girls tested after 23 weeks of treatment.
  
  
  CONCLUSIONS
  ERT with agalsidase alfa in children with Fabry disease is well tolerated and, in the short term, appears to decrease pain and to improve pain-related QoL.
authors.affiliation: Department of Paediatric Endocrinology, Diabetes and Metabolism, Addenbrooke's University Teaching Hospital, Cambridge, UK. uma.ramaswami@addenbrookes.nhs.uk
authors.forename: U
authors.initials: U
authors.lastname: Ramaswami
authors.forename: S
authors.initials: S
authors.lastname: Wendt
authors.forename: G
authors.initials: G
authors.lastname: Pintos-Morell
authors.forename: R
authors.initials: R
authors.lastname: Parini
authors.forename: C
authors.initials: C
authors.lastname: Whybra
authors.forename: J A
authors.initials: JA
authors.lastname: Leon Leal
authors.forename: F
authors.initials: F
authors.lastname: Santus
authors.forename: M
authors.initials: M
authors.lastname: Beck
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D000795:Fabry Disease / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007527:Isoenzymes / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D010147:Pain Measurement; D011994:Recombinant Proteins; D013546:Sweating / Q000187:drug effects; D016896:Treatment Outcome; D014281:Trihexosylceramides / Q000097:blood / Q000652:urine; D000519:alpha-Galactosidase / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D007527:Isoenzymes; D011994:Recombinant Proteins; D014281:Trihexosylceramides; C000627036:agalsidase alfa; C018549:globotriaosylceramide; D000519:alpha-Galactosidase